{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:42:26Z","timestamp":1786707746901,"version":"build-2736575974"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Isoniazid preventive therapy (IPT) is effective in treating tuberculosis (TB) infection and hence limiting progression to active disease. However, the durability of protection, associated factors and cost-effectiveness of IPT remain uncertain in low-and-middle income countries, Uganda inclusive. The Uganda Ministry of health recommends a single standard-dose IPT course for eligible people living with HIV (PLHIV). In this study we determined the incidence, associated factors and median time to TB diagnosis among PLHIV on Antiretroviral therapy (ART) who initiated IPT.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>We conducted a retrospective cohort study at eleven The AIDS Support Organization (TASO) centers in Uganda. We reviewed medical records of 2634 PLHIV on ART who initiated IPT from 1<jats:sup>st<\/jats:sup> January 2016 to 30<jats:sup>th<\/jats:sup> June 2018, with 30<jats:sup>th<\/jats:sup> June 2021 as end of follow up date. We analyzed study data using STATA v.16. Incidence rate was computed as the number of new TB cases divided by the total person months. A Frailty model was used to determine factors associated with TB incidence.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The 2634 individuals were observed for 116,360.7 person months. IPT completion rate was 92.8%. Cumulative proportion of patients who developed TB in this cohort was 0.83% (22\/2634), an incidence rate of 18.9 per 100,000 person months. The median time to TB diagnosis was 18.5 months (minimum\u2013 0.47; maximum\u2013 47.3, IQR: 10.1\u201332.4). World Health Organization (WHO) HIV clinical stage III (adjusted hazard ratio (aHR) 95%CI: 3.66 (1.08, 12.42) (P = 0.037) and discontinuing IPT (aHR 95%CI: 25.96(4.12, 169.48) (p = 0.001)), were associated with higher odds of TB diagnosis compared with WHO clinical stage II and IPT completion respectively.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Incidence rates of TB were low overtime after one course of IPT, and this was mainly attributed to high completion rates.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0266285","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T17:25:33Z","timestamp":1652721933000},"page":"e0266285","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study"],"prefix":"10.1371","volume":"17","author":[{"given":"Andrew","family":"Kazibwe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3702-1537","authenticated-orcid":true,"given":"Bonniface","family":"Oryokot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levicatus","family":"Mugenyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kagimu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham Ignatius","family":"Oluka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlius","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4510-6736","authenticated-orcid":true,"given":"Simple","family":"Ouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Tayebwakushaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Odoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kizito","family":"Kakumba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Opito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceasar Godfrey","family":"Mafabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ochwo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Nkabala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilber","family":"Tusiimire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Kateeba Tusiime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Barbara","family":"Alinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus","family":"Miya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Bernard","family":"Etukoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Andia","family":"Biraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Kirenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"pone.0266285.ref001","unstructured":"WHO: Guidelines on the management of latent tuberculosis infection. (2015)"},{"key":"pone.0266285.ref002","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijid.2016.11.006","article-title":"Preventive therapy for latent tuberculosis infection\u2014the promise and the challenges.","volume":"56","author":"G.J. Fox","year":"2017","journal-title":"Int. J. Infect. Dis"},{"key":"pone.0266285.ref003","unstructured":"WHO: Global Tuberculosis Report 2021., Geneva, Switzerland (2021)"},{"key":"pone.0266285.ref004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-019-4031-2","article-title":"The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: A meta-analysis","volume":"19","author":"D. Geremew","year":"2019","journal-title":"BMC Infect. Dis"},{"key":"pone.0266285.ref005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0223076","article-title":"Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe.","volume":"14","author":"S. Nyathi","year":"2019","journal-title":"PLoS One."},{"key":"pone.0266285.ref006","first-page":"1","article-title":"Effect of Isoniazid Preventive Therapy on Tuberculosis Prevalence among HIV Patients Attending Bahati Comprehensive Care Centre, Nairobi, Kenya.","volume":"23","author":"E. Lucy Obonyo Nyang\u2019au","year":"2020","journal-title":"J. Tuberc."},{"key":"pone.0266285.ref007","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/TCRM.S127765","article-title":"Assessment of isoniazid preventive therapy in the reduction of tuberculosis among art patients in Arba Minch Hospital, Ethiopia.","volume":"13","author":"A. Abossie","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"pone.0266285.ref008","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-029400","article-title":"Treatment success rate among adult pulmonary tuberculosis patients in sub-Saharan Africa: A systematic review and meta-analysis.","volume":"9","author":"J. Izudi","year":"2019","journal-title":"BMJ Open"},{"key":"pone.0266285.ref009","doi-asserted-by":"crossref","first-page":"596","DOI":"10.5588\/ijtld.17.0758","article-title":"TB preventive therapy for people living with HIV: Key considerations for scale-up in resource-limited settings","volume":"22","author":"I. Pathmanathan","year":"2018","journal-title":"Int. J. Tuberc. Lung Dis"},{"key":"pone.0266285.ref010","author":"N. Salazar-Austin","year":"2019","journal-title":"Seventy years of tuberculosis prevention: Efficacy, effectiveness, toxicity, durability, and duration"},{"key":"pone.0266285.ref011","unstructured":"WHO: WHO operational handbook on tuberculosis (Module 1 \u2013Prevention): Tuberculosis preventive treatment. (2020)"},{"key":"pone.0266285.ref012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1003712","article-title":"Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis","volume":"18","author":"A. Uppal","year":"2021","journal-title":"PLoS Med"},{"key":"pone.0266285.ref013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1003703","article-title":"The latent tuberculosis cascade-of-care among people living with HIV: A systematic review and meta-analysis","volume":"18","author":"M.L. Bastos","year":"2021","journal-title":"PLoS Med"},{"key":"pone.0266285.ref014","unstructured":"UNAIDS: Global Aids Strategy 2021\u20132026 End Inequalities. End Aids. (2021)"},{"key":"pone.0266285.ref015","unstructured":"WHO: Implementing The End TB Strategy: THE ESSENTIALS. (2015)"},{"key":"pone.0266285.ref016","unstructured":"PEPFAR: PEPFAR 2021 Country and Regional Operational Plan (COP \/ ROP) Guidance for all PEPFAR Countries. (2020)"},{"key":"pone.0266285.ref017","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4046\/trd.2017.0052","article-title":"Treatment of latent tuberculosis infection and its clinical efficacy","volume":"81","author":"H.W. Kim","year":"2018","journal-title":"Tuberc. Respir. Dis. (Seoul)."},{"key":"pone.0266285.ref018","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5588\/ijtld.16.0297","article-title":"Is IPT more effective in high-burden settings? Modelling the effect of tuberculosis incidence on IPT impact","volume":"21","author":"R. Ragonnet","year":"2017","journal-title":"Int. J. Tuberc. Lung Dis"},{"key":"pone.0266285.ref019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0216060","article-title":"Trends of admissions and case fatality rates among medical in-patients at a tertiary hospital in Uganda; A four-year retrospective study.","volume":"14","author":"R. Kalyesubula","year":"2019","journal-title":"PLoS One."},{"key":"pone.0266285.ref020","unstructured":"MOH: The 2019 HIV Epidemiological Surveillance Report for Uganda., Kampa (2019)"},{"key":"pone.0266285.ref021","first-page":"19","article-title":"Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania:A retrospective cohort study","volume":"2019","author":"A. Sabasaba","year":"2019","journal-title":"BMC Infect. Dis"},{"key":"pone.0266285.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-016-2109-7","article-title":"Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV\/AIDS in public health facilities of Addis Ababa, Ethiopia: A historical cohort study.","volume":"17","author":"M. Semu","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"pone.0266285.ref023","doi-asserted-by":"crossref","first-page":"e001135","DOI":"10.1136\/bmjgh-2018-001135","article-title":"Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India.","volume":"3","author":"P.K. Moonan","year":"2018","journal-title":"BMJ Glob. Heal"},{"key":"pone.0266285.ref024","unstructured":"Ministry of Health Uganda: Guidelines for Programmatic Management of Latent TB Infection in Uganda \u201cClosing the TB tap\u201d A Health Worker Guide., Kampala, Uganda (2021)"},{"key":"pone.0266285.ref025","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4236\/wja.2020.102008","article-title":"Interventions to Improve HIV Viral Load Suppression among the Adolescents: Evidence of Improvement Science through a Quality Improvement Approach in Eastern Uganda.","volume":"10","author":"B. Oryokot","year":"2020","journal-title":"World J. AIDS"},{"key":"pone.0266285.ref026","unstructured":"TASO: TASO Strategic Plan 2018\u20132022. (2018)"},{"key":"pone.0266285.ref027","doi-asserted-by":"crossref","first-page":"219","DOI":"10.15562\/bmj.v9i1.1684","article-title":"Effect of isoniazid preventive therapy on pulmonary tuberculosis activity in people living with hiv\/aids at wangaya hospital in Denpasar, Bali, Indonesia: A prospective cohort study.","volume":"9","author":"K. Suryana","year":"2020","journal-title":"Bali Med. J."},{"key":"pone.0266285.ref028","author":"Herbert Muyinda","year":"2020","journal-title":"Quality of Tuberculosis Services Assessment in Uganda:Report of Qualitative Findings"},{"key":"pone.0266285.ref029","unstructured":"MOH: TUBERCULOSIS AND LEPROSY CASE MANAGEMENT DESK GUIDE. (2019)"},{"key":"pone.0266285.ref030","unstructured":"Github: KoboToolbox, http:\/\/www.kobotoolbox.org\/"},{"key":"pone.0266285.ref031","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/QAD.0000000000000535","article-title":"Tuberculosis incidence after 36 months\u2019 isoniazid prophylaxis in HIV-infected adults in Botswana: A posttrial observational analysis","volume":"29","author":"T. Samandari","year":"2015","journal-title":"AIDS"},{"key":"pone.0266285.ref032","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(14)60162-8","article-title":"Isoniazid plus antiretroviral therapy to prevent tuberculosis: A randomised double-blind, placebo-controlled trial","volume":"384","author":"M.X. Rangaka","year":"2014","journal-title":"Lancet"},{"key":"pone.0266285.ref033","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12981-020-00285-0","article-title":"A prospective cohort study of outcomes for isoniazid prevention therapy: A nested study from a national QI collaborative in Uganda.","volume":"17","author":"S. Sensalire","year":"2020","journal-title":"AIDS Res. Ther"},{"key":"pone.0266285.ref034","doi-asserted-by":"crossref","first-page":"100269","DOI":"10.1016\/j.jctube.2021.100269","article-title":"Low level of tuberculosis preventive therapy incompletion among people living with Human Immunodeficiency Virus in eastern Uganda: A retrospective data review","volume":"25","author":"P. Lwevola","year":"2021","journal-title":"J. Clin. Tuberc. Other Mycobact. Dis"},{"key":"pone.0266285.ref035","doi-asserted-by":"crossref","first-page":"388","DOI":"10.5588\/ijtld.20.0956","article-title":"Gaps in TB preventive therapy for persons initiating antiretroviral therapy in Uganda: An explanatory sequential cascade analysis","volume":"25","author":"N. Kalema","year":"2021","journal-title":"Int. J. Tuberc. Lung Dis"},{"key":"pone.0266285.ref036","first-page":"1","article-title":"Effectiveness of isoniazid preventive treatment among patients on antiretroviral treatment in Southeast Nigeria: A retrospective cohort study.","volume":"1","author":"C.D. Umeokonkwo","year":"2018","journal-title":"J. Interv. Epidemiol. Public Heal"},{"key":"pone.0266285.ref037","unstructured":"WHO: Guidelines for Managing Advaned HIV Disease and Rapid initiation of Antiretroviral Therapy. (2017)"},{"key":"pone.0266285.ref038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0262720","article-title":"Prevalence and associated risk factors for tuberculosis among people living with HIV in Nepal.","volume":"17","author":"N. Adhikari","year":"2022","journal-title":"PLoS One"},{"key":"pone.0266285.ref039","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/cid\/ciu849","article-title":"Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: The TB\/HIV in Rio (THRio) study.","volume":"60","author":"J.E. Golub","year":"2015","journal-title":"Clin. Infect. Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0266285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T17:26:15Z","timestamp":1652721975000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0266285"}},"subtitle":[],"editor":[{"given":"Kevin","family":"Schwartzman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0266285","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]}}}